AdaptHealth stock fell 47% this week after the company reported second-quarter results that missed expectations and slashed its full-year guidance. The company posted a loss of $1.07 per share, far below the $0.15 profit analysts had forecast, while revenue of $740.3 million came in about $106.5 million below estimates. AdaptHealth now expects full-year sales between $2.85 billion and $2.89 billion, down from its prior range of $3.45 billion to $3.52 billion, largely due to discontinuing its Diabetes Health business. Adjusted EBITDA guidance was cut to $490 million to $520 million from $680 million to $730 million, and free cash flow is now seen at $80 million to $120 million, down from $175 million to $225 million.
Adapthealth CorpQ2 miss and guidance cut
NVIDIA Corporation